Evidence map›Paper›PMID 17140440›Full record

ArticleMolecular cancer2006

Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.

Brenda L Petrella, Constance E Brinckerhoff

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. The emerging roles of circRNAs in cancer and oncology.Nature reviews. Clinical oncology · 2022
    Review
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Review
  9. Article
  10. VHL, the story of a tumour suppressor gene.Nature reviews. Cancer · 2015
    Review
  11. Article
  12. State of the science: an update on renal cell carcinoma.Molecular cancer research : MCR · 2012
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Brenda L PetrellaDepartment of Medicine, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH, USA. brenda.l.petrella@dartmouth.edu
Constance E Brinckerhoff
Dartmouth College · US

Funding

Invasive Behavior of Tumor Cells Producing Collagenase-1R01CA077267 · NCI · DARTMOUTH COLLEGE · PI BRINCKERHOFF, CONSTANCE E · 1999 to 2013
$2.6M
REGULATION OF COLLAGENASE GENE EXPRESSIONR37AR026599 · NIAMS · DARTMOUTH COLLEGE · PI BRINCKERHOFF, CONSTANCE E · 1999 to 2006
$1.9M
AUTOIMMUNITY &CONNECTIVE TISSUE BIOLOGY TRAININGT32AR007576 · NIAMS · DARTMOUTH COLLEGE · PI RIGBY, WILLIAM FREDERICK CARSON · 1994 to 2008
$1.7M
REGULATION OF METALLOPROTEINASE GENE EXPRESSIONR01AR026599 · NIAMS · DARTMOUTH COLLEGE · PI BRINCKERHOFF, CONSTANCE E · 1986 to 2011
$1.7M
NCI NIH HHS CA-77267NCI NIH HHS R01 CA077267NIAMS NIH HHS AR26599NIAMS NIH HHS R01 AR026599NIAMS NIH HHS R37 AR026599NIAMS NIH HHS T32 AR007576NIAMS NIH HHS T32-AR-007576
6 · The paper itself

Abstract

backgroundMetastatic renal cell carcinoma (RCC) remains the leading cause of mortality in patients with clear cell RCC arising from mutations in the von Hippel Lindau (VHL) tumor suppressor. Successful RCC tumor suppression by VHL requires the negative regulation of hypoxia inducible factor alpha (HIF alpha) protein and its downstream targets. Thus, identification of HIF target genes responsible for RCC tumor progression will aid in the development of therapies for this disease. We previously identified membrane type-1 matrix metalloproteinase (MT1-MMP) as a transcriptional target of HIF-2alpha in RCC cells null for VHL and showed that MT1-MMP is overexpressed in these cells. MT1-MMP is a key regulator of tumor progression through its functions as a matrix-degrading enzyme, as well as its ability to cleave factors, such as adhesion molecules and other MMPs. The aim of this study was to investigate the contribution of MT1-MMP to the invasive potential of RCC cells using in vitro type I collagen degradation and invasion assays.

resultsWe evaluated RCC cells wild-type (WT8) and null (pRc-9) for VHL for invasive characteristics and showed that the pRc-9 cells demonstrated a greater propensity for both invasion and degradation of a type I collagen matrix. Furthermore, overexpression of either HIF-2alpha or MT1-MMP in the poorly invasive cell line, WT8, promoted collagen degradation and invasion of these cells. Finally, using RNAi, we show that inhibition of MT1-MMP suppresses tumor cell invasion of RCC cells.

conclusionOur results suggest that MT1-MMP is a major mediator of tumor cell invasiveness and type I collagen degradation by VHL RCC cells that express either MT1-MMP or HIF-2alpha. As such, MT1-MMP may represent a novel target for anti-invasion therapy for this disease.

Indexed as

Gene Expression Regulation, NeoplasticBasic Helix-Loop-Helix ProteinsCarcinoma, Renal CellCell Line, TumorCollagen Type IEndothelial PAS Domain-Containing Protein 1HumansKidney NeoplasmsMatrix Metalloproteinase 14Neoplasm InvasivenessNeoplasm MetastasisRNA Interferencevon Hippel-Lindau DiseaseBasic Helix-Loop-Helix ProteinsCollagen Type IEndothelial PAS Domain-Containing Protein 1Matrix Metalloproteinase 14

Identifiers

PMID17140440
PMCPMC1764426
OpenAlexW2168438736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.